Abstract
Objectives
The primary objective in this study was to evaluate the effects of vaginal progesterone supplementation for the prolongation of the latency period in preterm labor. The secondary objectives were to evaluate gestational age at delivery, rates of preterm birth less than 34 and 37 weeks, obstetric outcomes, maternal compliance with medication use, and side effects.
Methods
A randomized controlled, unblinded trial was performed. Ninety women with preterm labor occurring at 24 to 34 weeks were either randomized to a vaginal progesterone group (44 women) receiving tocolytic and antenatal corticosteroids treatment combined with vaginal micronized progesterone (400 mg everyday) or to the no-progesterone group (46 women) receiving tocolytic and antenatal corticosteroids treatment only.
Results
Latency periods were more prolonged in the vaginal progesterone group than in the no-progesterone group (32.8 ± 18.7 vs. 25.8 ± 22.7 days, p = 0.045). Gestational age at delivery in the vaginal progesterone group was also higher than in the no-progesterone group (37 vs. 35 weeks, p = 0.027). There were significant reduction rates of preterm birth less than 34 weeks (13.6% vs. 39.1%, p = 0.012), low birth weight (29.5% vs. 50%, p = 0.048), neonatal respiratory distress syndrome (13.6% vs. 37%, p = 0.021), and neonatal intensive care unit admission (6.8% vs. 28.3%, p = 0.017).
Conclusions
Combined treatment with vaginal progesterone 400 mg could prolong the latency period in preterm labor when compared with no progesterone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
ACOG. (2012). ACOG practice bulletin no. 130: Prediction and prevention of preterm birth. Obstetrics and Gynecology, 120, 964–973
ACOG. (2016). ACOG practice bulletin no. 171: Management of preterm labor. Obstetrics and Gynecology, 128, e155–e164
Areeruk, W., & Phupong, V. (2016). A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Scientific Reports, 6, 20638
Areia, A., Fonseca, E., & Moura, P. (2013). Progesterone use after successful treatment of threatened pre-term delivery. Journal of Obstetrics and Gynaecology, 33, 678–681
Arikan, I., Barut, A., Harma, M., & Harma, I. M. (2011). Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecologic and Obstetric Investigation, 72, 269–273
Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A. B., Narwal, R., et al. (2012). National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet, 379, 2162–2172
Bomba-Opon, D. A., Kosinska-Kaczynska, K., Kosinski, P., Wegrzyn, P., Kaczynski, B., & Wielgos, M. (2012). Vaginal progesterone after tocolytic therapy in threatened preterm labor. Journal of Maternal-Fetal and Neonatal Medicine, 25, 1156–1159
Borna, S., & Sahabi, N. (2008). Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology, 48(58), 63
da Fonseca, E. B., Bittar, R. E., Carvalho, M. H. B., & Zugaib, M. (2003). Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. American Journal of Obstetrics and Gynecology, 188, 419–424
de Tejada, B. M., Karolinski, A., Ocampo, M. C., Laterra, C., Hosli, I., Fernandez, D., et al. (2015). Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): Randomised double-blind placebo-controlled trial. British Journal of Obstetrics and Gynaecology, 122, 80–91
Friedler, S., Raziel, A., Schachter, M., Strassburger, D., Bukovsky, I., & Ron-El, R. (1999). Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: A comparative study between vaginal and oral administration. Human Reproduction, 14, 1944–1948
Fuchs, A. R., & Fuchs, F. (1984). Endocrinology of human parturition: A review. British Journal of Obstetrics and Gynaecology, 91, 948–967
Garfield, R. E., Saade, G., Buhimschi, C., Buhimschi, I., Shi, L., Shi, S. Q., et al. (1998). Control and assessment of the uterus and cervix during pregnancy and labour. Human Reproduction Update, 4, 673–695
Jarde, A., Lutsiv, O., Beyene, J., & McDonald, S. D. (2019). Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis. British Journal of Obstetrics and Gynaecology, 126, 556–567
Lucovnik, M., Bregar, A. T., Bombac, L., Gersak, K., & Garfield, R. E. (2018). Effects of vaginal progesterone for maintenance tocolysis on uterine electrical activity. The Journal of Obstetrics and Gynaecology Research, 44, 408–416
Noblot, G., Audra, P., Dargent, D., Faguer, B., & Mellier, G. (1991). The use of micronized progesterone in the treatment of menace of preterm delivery. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 40, 203–209
Palacio, M., Cobo, T., Antolin, E., Ramirez, M., Cabrera, F., de Rosales, F. M., et al. (2016). Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE) study: A multicentre, double-blind, randomised, placebo-controlled trial. British Journal of Obstetrics and Gynaecology, 123, 1990–1999
Romero, R., Conde-Agudelo, A., Da Fonseca, E., O’Brien, J. M., Cetingoz, E., Creasy, G. W., et al. (2018). Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: A meta-analysis of individual patient data. American Journal of Obstetrics and Gynecology, 218, 161–180
Sharami, S. H., Zahiri, Z., Shakiba, M., & Milani, F. (2010). Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: A randomized placebo-controlled double-blind trial. International Journal of Fertility & Sterility, 4, 45–50
Theplib, A., & Phupong, V. (2016). Success rate of terbutaline in inhibiting preterm labor for 48 h. Journal of Maternal-Fetal and Neonatal Medicine, 29, 841–844
World Health Organization. International Classification of Diseases 10th revision (ICD-10). 2010. https://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf
Acknowledgements
The work was funding by Internal research grant: Ratchadapiseksompotch Fund, Faculty of Medicine, University, study Grant Number RA60/092. The authors thank the doctors and nurses of the antenatal care unit and labor room, Department of OB&GYN, Faculty of Medicine, University for their help.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sirisangwon, R., Phupong, V. Vaginal Progesterone Supplementation in the Management of Preterm Labor: A Randomized Controlled Trial. Matern Child Health J 25, 1102–1109 (2021). https://doi.org/10.1007/s10995-021-03153-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10995-021-03153-z